Tofacitinib for refractory uveitis and scleritis

Michael A Paley; Humeyra Karacal; P Kumar Rao; Todd P Margolis; Jonathan J Miner

doi:10.1016/j.ajoc.2018.12.001

Tofacitinib for refractory uveitis and scleritis

Am J Ophthalmol Case Rep. 2018 Dec 4:13:53-55. doi: 10.1016/j.ajoc.2018.12.001. eCollection 2019 Mar.

Authors

Michael A Paley^{1

2}, Humeyra Karacal^{3

2}, P Kumar Rao^{3

2}, Todd P Margolis^{3

2}, Jonathan J Miner^{1

4

5

2}

Affiliations

¹ Department of Medicine, Saint Louis, MO, 63110, USA.
² Washington University in Saint Louis School of Medicine, Saint Louis, MO, 63110, USA.
³ Department of Ophthalmology and Visual Sciences, Saint Louis, MO, 63110, USA.
⁴ Department of Molecular Microbiology, Saint Louis, MO, 63110, USA.
⁵ Department of Pathology and Immunology, Saint Louis, MO, 63110, USA.

Abstract

Purpose: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis.

Observations: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis.

Conclusions and importance: Tofacitinib is a potential novel treatment option for refractory, noninfectious inflammatory eye disease.

Keywords: JAK; STAT; Scleritis; Tofacitinib; Uveitis.

Publication types

Case Reports

Grants and funding

T32 AR007279/AR/NIAMS NIH HHS/United States